Key result
Shared genetics, metabolic features, and risk factors link cancer and CVD amid complex drug interactions.
Why the study?
Advances in cancer treatment have improved long-term survival, but cardiovascular disease has emerged as a leading cause of morbidity and mortality in cancer patients.
This review highlights the shared genetic and metabolic pathways between cancer and cardiovascular disease, providing a framework for understanding cardio-oncology and identifying potential dual therapeutic targets.
May support dual-target strategies in cardio-oncology; extends shared pathway evidence but leaves clinical adoption open.
PURPOSE OF REVIEW: The article aims to investigate the complex relationship between cancer and cardiovascular disease (CVD), with a focus on the effects of cancer treatment on cardiac health. RECENT FINDINGS: Advances in cancer treatment have improved long-term survival rates, but CVD has emerged as a leading cause of morbidity and mortality in cancer patients. The interplay between cancer itself, treatment methods, homeostatic changes, and lifestyle modifications contributes to this comorbidity. Recent research in the field of cardio-oncology has revealed common genetic mutations, risk factors, and metabolic features associated with the co-occurrence of cancer and CVD. This article provides a comprehensive review of the latest research in cardio-oncology, including common genetic mutations, risk factors, and metabolic features, and explores the interactions between cancer treatment and CVD drugs, proposing novel approaches for the management of cancer and CVD.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2023) conducted a review in Cancer and Cardiovascular Disease. Shared genetic mutations, metabolic features, and risk factors link cancer and cardiovascular disease, with complex interactions existing between anticancer therapies and cardiovascular drugs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: